Sajjad Sabir, MD
Cardiovascular Disease · Camden, NJNPI 1215033030
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $42,875 of the $69,486 with a category attached, or 61.7%. 20 manufacturers reported payments, led by Boston Scientific at 58.8% of the total. 2025 is the largest year on record at $23,372, 4.9 times the $4,760 reported in 2019. Among cardiovascular disease clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 227 payments — averaging $306.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$41K
- Abbott$22K
- Edwards Lifesciences$6K
- Atricure, Inc.$283
- Amgen$194
- Medtronic$150
- plus $443 from 14 others
Across 184 payments — averaging $3657.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$537K
- Edwards Lifesciences$132K
- Boston Scientific$3K
What the payments were for
- Consulting fees$4,5006%
- Speaking & faculty fees$42,87562%
- Travel & lodging$13,61220%
- Food & beverage$8,47612%
- Education$230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 51 | $40,854 |
| Abbott | 88 | $22,028 |
| Edwards Lifesciences | 39 | $5,534 |
| Atricure, Inc. | 6 | $283 |
| Amgen | 14 | $194 |
| Medtronic | 2 | $150 |
| Philips North America LLC | 5 | $84 |
| Novartis | 6 | $82 |
| Johnson & Johnson | 4 | $55 |
| Chiesi USA, Inc. | 2 | $32 |
| GE HealthCare | 1 | $30 |
| Change Healthcare Technologies, LLC | 1 | $25 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Cvrx, Inc. | 1 | $21 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $20 |
| W. L. Gore & Associates, Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Angiodynamics, Inc. | 1 | $15 |
| Pfizer | 1 | $13 |
| Astellas Pharma US Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN Access System$24,472
- Watchman$12,576
- MitraClip$8,551
- Mitra Clip system$5,125
- MitraClip System$2,133
- TRICLIP$2,000
- GENERAL - THERAPIES$1,592
- GENERAL VASCULAR ACCESS$1,000
- JETi All In One Non-Sterile Kit$1,000
- SAPIEN 3 Ultra RESILIA$676
- WATCHMAN FLX$624
- PASCAL$606
- Edwards SAPIEN 3 Transcatheter Heart Valve$447
- AMPLATZER AMULET$172
- NAVITOR$169
- INTELLIS$121
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$111
How this compares
$69,486 in reported general payments places this provider in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 17 | $22,940 |
| Ezetimibe | 23 | $668 |
| Metoprolol Succinate | 34 | $414 |
| Atorvastatin Calcium | 26 | $412 |
| Torsemide | 19 | $245 |
| Carvedilol | 16 | $172 |
| Furosemide | 11 | $109 |
| Amlodipine Besylate | 23 | $107 |
| Losartan Potassium | 13 | $34 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $13 | $22,94017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.
Other cardiovascular disease in Camden
- Andrea RussoCamden$293K
- John AndriulliCamden$111K
- Perry WeinstockCamden$94K
- Marc CohenNewark$762K
- Peter FarrugiaColts Neck$600K
- Felix Dailey-SterlingGuttenberg$568K
- Ramzan ZakirNew Brunswick$342K
- Richard KovachBrowns Mills$300K
- John KostisNew Brunswick$225K
- Dilip ViswanathHaddon Heights$167K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.